Drugmakers including Novo Nordisk (NVO) and Eli Lilly (LLY) should remove label warnings of a potential risk of suicidal thoughts and behavior from GLP-1 weight loss drugs, the Food and Drug Administration said Tuesday.
The FDA said that a comprehensive review of the drugs showed "no increased risk" of suicidal behaviors or ideation.
The FDA letter covers Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Novo's older weight-loss drug Saxenda.
Price: 59.86, Change: -0.01, Percent Change: -0.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments